Introduction
Rhabdomyosarcoma (RMS) is a rare pediatric cancer thought to phenocopy a skeletal muscle lineage. RMS presents as one of two main subtypes, each exhibiting a unique histological and molecular profile. Embryonal rhabdomyosarcoma (eRMS) is characterized by widespread genetic instability with P53, RAS, PIK3CA, RB1 and FGFR4 disruptions often observed (1-6). Alveolar rhabdomyosarcoma (aRMS) is defined by a t(2;13) or t(1;13) chromosomal translocation that results in the DNA binding domain of either PAX7 or PAX3 fusing with the transactivation domain of FOXO1, creating an oncogenic transcription factor (7, 8) . Even though RMS is the most common soft tissue sarcoma in children, survival for patients with metastasis has remained unchanged over the past 47 years despite intensive multimodal therapy.
Histologically, rhabdomyosarcoma expresses markers of myogenic differentiation such as myogenin and MyoD1 (9, 10) ; however, the function of these myogenic proteins is often impaired and RMS cells fail to fully differentiate (11) . RMS is believed to circumvent terminal differentiation, allowing RMS tumor cells to divide uncontrollably. Restoring the terminal differentiation program is posited to slow or halt tumor growth by transforming malignant, proliferating cells into non-dividing cells. Differentiation therapy appears to have clinical potential, as eRMS cells have been observed to differentiate following chemotherapy and radiation (12) (13) (14) , although this response is not often found in aRMS.
Different groups have uncovered strategies for inducing differentiation in RMS and thus slowing growth, but with limited success. Genetic suppression of the Notch1-Hey1 pathway by shRNA in eRMS RD cells, or suppression of Notch-3 by siRNA in RD and aRMS Rh30 cells results in an increase of myogenic differentiation markers in vitro, and pharmacological inhibition of Notch signaling using a g -secretase inhibitor reduces cell proliferation (15, 16) . In RD cells, modulating miR-206 increases differentiation by 30% in vitro (17) , while GSK3 inhibitors significantly increase the number of myosin heavy chain positive cells after treatment for 72 hours (18) . The inhibition of RAF/MEK protein kinases induce terminal differentiation in RD cells (18) , a result not surprising given that RAS pathway activation is common in eRMS, and that this disease demonstrates a "Ras on" gene signature (5, 19) . In vivo trametinib slows but does not halt tumor growth in eRMS cell lines SMS-CTR and BIRCH, but not RD; these tumors exhibit an increase in nuclear MYOG expression, but not across all cells of a tumor, and complete terminal differentiation is not observed (20) . Taken together, these results demonstrate the difficulty in achieving complete terminal differentiation and suggest the therapeutic benefit of a single agent differentiation therapy will have limited clinical success, and thus combining pathway inhibitors will likely be necessary to achieve tumor remission.
Unpublished data from our lab suggests in vitro synergy when simultaneously targeting the MAPK and Notch pathways in RMS cells. Presented here are the in vitro drug screening assays performed on a range of aRMS and eRMS cells lines and primary patient cells harboring different genetic hallmarks, to examine the efficacy of the MEK inhibitor trametinib alone or in combination with Notch signaling inhibition using g-secretase inhibitors.
Results

Trametinib decreases viability in a range of cell lines
Our experiments confirmed that treatment of KRAS-driven RD cells with sub-micromolar concentrations (684 nM) of trametinib for 72 hours resulted in cytotoxicity ( Figure 1A ).
Unexpectedly, SCA1-01, a Kras activated primary mouse tumor cell line, was not sensitive to MEK inhibition (IC50= 38,000 nM), indicating that a pathway other than RAS-MEK is necessary for tumor cell maintenance (Figure 3 ). An aRMS patient-derived primary tumor cell culture (CF-1, Figure 2A ) and an aRMS cell line (Rh30, Figure 4A ) that both harbored the PAX3:FOXO1 chromosomal translocation were also treated with trametinib and responded with low micromolar concentrations (IC50= 1,557 nM and 803 nM, respectively). Finally, we tested CW9019, a cell line that has an alveolar histology and harbored a t(1;13) reciprocal translocation resulting in a PAX7:FOXO1 fusion protein. This cell line was the most sensitive to trametinib treatment, with a half maximal inhibitory concentration of 113 nM ( Figure 5A ). However, the in vitro IC50 values for these cell lines are still well above the clinically achievable dose of trametinib (36 nM) (21) . 
Trametinib in combination with
